CD8A and neoplasm: Furthermore, Nadine et al. demonstrated that NKG2A blockers prevented the ligand Qa-1/HLA-E on tumor cells from binding to the inhibitory receptor NKG2A on the surface of CD8 + T cells, avoiding adaptive immune tolerance development [245].